These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2841838)

  • 1. Role of the beta 2 adrenoceptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride.
    Lang RM; Borow KM; Neumann A; Carroll JD; Weinert L; Murphy MB; Ghali J; Rajfer SI
    Am J Cardiol; 1988 Aug; 62(5):46C-52C. PubMed ID: 2841838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine.
    Jaski BE; Peters C
    Am J Cardiol; 1988 Aug; 62(5):63C-67C. PubMed ID: 3407597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine on left ventricular afterload and contractile state in heart failure: relation to the activation of beta 1-adrenoceptors and dopamine receptors.
    Rajfer SI; Borow KM; Lang RM; Neumann A; Carroll JD
    J Am Coll Cardiol; 1988 Aug; 12(2):498-506. PubMed ID: 2839569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours' duration for severe congestive heart failure.
    Gollub SB; Emmot WW; Johnson DE; Sights KA; Wilson DB; Vacek JL; Hassanein K
    Am J Cardiol; 1988 Aug; 62(5):83C-88C. PubMed ID: 3407599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic comparison of dopexamine and nitroprusside at high and low doses in patients with coronary artery disease and impaired left ventricular function.
    Ikram H; Foy SG; Low CJ; Redfern SA; Shirlaw TM; Bennett SI; Crozier IG
    J Cardiovasc Pharmacol; 1995 Nov; 26(5):777-83. PubMed ID: 8637193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arrhythmogenic potential of dopexamine hydrochloride during halothane anaesthesia in dogs.
    Neustein SM; Dimich I; Sampson I; Sadeghi A; Mezrow C; Shiang H
    Can J Anaesth; 1994 Jun; 41(6):542-6. PubMed ID: 7915210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic comparison of dopexamine hydrochloride and dopamine in ischemic left ventricular dysfunction.
    Jackson NC; Taylor SH; Frais MA
    Am J Cardiol; 1988 Aug; 62(5):73C-77C. PubMed ID: 2457305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.
    Goldberg LI; Bass AS
    Am J Cardiol; 1988 Aug; 62(5):37C-40C. PubMed ID: 2841837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoreceptors (dopexamine) in patients with heart failure.
    Jamison M; Widerhorn J; Weber L; Campese V; Vasquez J; Hovanessian L; Rahimtoola SH; Elkayam U
    Am Heart J; 1989 Mar; 117(3):607-14. PubMed ID: 2537556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dopexamine: a new dopaminergic agonist].
    Perrin G; Papazian L; Martin C
    Ann Fr Anesth Reanim; 1993; 12(3):308-20. PubMed ID: 7902685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of dopexamine hydrochloride (Dopacard) and an overview of its hemodynamic effects.
    Foulds RA
    Am J Cardiol; 1988 Aug; 62(5):41C-45C. PubMed ID: 3044060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost.
    De Marco T; Kwasman M; Lau D; Chatterjee K
    Am J Cardiol; 1988 Aug; 62(5):57C-62C. PubMed ID: 3407596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure.
    Tan LB; Littler WA; Murray RG
    Int J Cardiol; 1991 Feb; 30(2):203-8. PubMed ID: 2010243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of dopexamine on the cardiovascular system of the dog.
    Brown RA; Farmer JB; Hall JC; Humphries RG; O'Connor SE; Smith GW
    Br J Pharmacol; 1985 Jul; 85(3):609-19. PubMed ID: 4027482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotropic mechanisms of dopexamine hydrochloride in horses.
    Muir WW
    Am J Vet Res; 1992 Aug; 53(8):1343-6. PubMed ID: 1354950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study.
    Gollub SB; Elkayam U; Young JB; Miller LW; Haffey KA
    J Am Coll Cardiol; 1991 Aug; 18(2):383-90. PubMed ID: 1677368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved beta 2-adrenoceptor subpopulation.
    Böhm M; Pieske B; Schnabel P; Schwinger R; Kemkes B; Klövekorn WP; Erdmann E
    J Cardiovasc Pharmacol; 1989 Oct; 14(4):549-59. PubMed ID: 2478768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular pharmacology of dopexamine in low output congestive heart failure.
    Leier CV; Binkley PF; Carpenter J; Randolph PH; Unverferth DV
    Am J Cardiol; 1988 Jul; 62(1):94-9. PubMed ID: 2898209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of dopexamine hydrochloride in intensive care patients with low-output left ventricular heart failure.
    Colardyn FA; Vandenbogaerde JF
    Am J Cardiol; 1988 Aug; 62(5):68C-72C. PubMed ID: 3407598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects on hemodynamics and urine output.
    Baumann G; Felix SB; Filcek SA
    Am J Cardiol; 1990 Mar; 65(11):748-54. PubMed ID: 1969223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.